A Phase 4 interventional study of mycophenolate mofetil [CellCept] and Corticosteroids in Kidney Transplantation, sponsored by Hoffmann-La Roche. Completed at 36 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-04-15.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This 2-arm study recruited kidney transplant patients who were receiving standard care of calcineurin inhibitors (CNIs, tacrolimus or cyclosporine), CellCept (1.0-1.5 g twice daily) and corticosteroids. They were either randomized to continue this regimen, or CNI therapy was discontinued and replaced by sirolimus therapy (in combination with CellCept and corticosteroids). The effect of these 2 regimens on efficacy, safety and kidney function was evaluated. The anticipated time on study treatment was 1-2 years, and the target sample size was 100-500 individuals.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: mycophenolate mofetil [CellCept] · Drug: Corticosteroids · Drug: Sirolimus
Drug: mycophenolate mofetil [CellCept] · Drug: Corticosteroids · Drug: Calcineurin inhibitors
1.0-1.5 g oral dose twice daily
As prescribed
As prescribed
As prescribed
Mean Percent Change in Glomerular Filtration Rate From Baseline to Month 12
The primary efficacy endpoint was mean percent change in renal function from baseline to 12 months postrandomization, as measured by Glomerular Filtration Rate utilizing renal clearance of cold iothalamate. percent change= \[(Glomerular Filtration Rate at Month 12-Glomerular Filtration Rate at baseline)/Glomerular Filtration Rate at baseline\]\*100 percent.
Time frame: baseline to 12 months
Mean Percent Change in Glomerular Filtration Rate From Baseline to Month 24
A secondary efficacy endpoint was mean percent change in renal function from baseline to 24 months postrandomization, as measured by Glomerular Filtration Rate utilizing renal clearance of cold iothalamate. percent change= \[(Glomerular Filtration Rate at Month 24-Glomerular Filtration Rate at baseline)/Glomerular Filtration Rate at baseline\]\*100 percent.
Time frame: Baseline to 24 months
Mean Percent Change in Serum Creatinine From Baseline to Months 6, 12, and 24
Renal allograft function determined by mean percent change from baseline in serum creatinine by treatment group at 6, 12, and 24 months postrandomization. percent change= \[(serum creatinine at Month t-serum creatinine at baseline)/serum creatinine at baseline\]\*100 percent, where t=6, 12, and 24 months postrandomization.
Time frame: baseline, 6, 12, and 24 months
Mean Percent Change in Calculated Creatinine Clearance From Baseline to Months 6, 12, and 24
Renal allograft function determined by mean percent change from baseline in calculated creatinine clearance (Cockroft and Gault method) by treatment group at 6, 12, and 24 months postrandomization. percent change= \[(calculated creatinine clearance at Month t - calculated creatinine clearance at baseline)/calculated creatinine clearance at baseline\]\*100 percent, where t=6, 12, and 24 months postrandomization
Time frame: baseline 6, 12, and 24 months
Mean Percent Change in Calculated Glomerular Filtration Rate From Baseline to Months 6, 12, and 24 (Nankivell Equation)
Renal allograft function determined by mean percent change from baseline in calculated Glomerular Filtration Rate (Nankivell equation) by treatment group at 6, 12, and 24 months postrandomization. percent change= \[(calculated Glomerular Filtration Rate at Month t - calculated Glomerular Filtration Rate at baseline)/calculated Glomerular Filtration Rate at baseline\]\*100 percent, where t=6, 12, and 24 months postrandomization.
Time frame: baseline, 6, 12, and 24 months
| Milestone | Mycophenolate Mofetil + Sirolimus | Mycophenolate Mofetil + Cyclosporine or Tacrolimus |
|---|---|---|
| Started | 151 | 154 |
| Safety population | 148 | 153 |
| Intent-to-treat (itt) population | 148 | 151 |
| Completed | 121 | 115 |
| Not completed | 30 | 39 |
The primary efficacy endpoint was mean percent change in renal function from baseline to 12 months postrandomization, as measured by Glomerular Filtration Rate utilizing renal clearance of cold iothalamate. percent change= \[(Glomerular Filtration Rate at Month 12-Glomerular Filtration Rate at baseline)/Glomerular Filtration Rate at baseline\]\*100 percent.
| percent change | Mycophenolate Mofetil + Sirolimus | Mycophenolate Mofetil + Cyclosporine or Tacrolimus |
|---|---|---|
| Baseline | 59.5 ± 23.86 | 58.8 ± 26.06 |
| Mean Percent Change from Baseline at Month 12 | 24.4 ± 70.00 | 5.2 ± 56.33 |
A secondary efficacy endpoint was mean percent change in renal function from baseline to 24 months postrandomization, as measured by Glomerular Filtration Rate utilizing renal clearance of cold iothalamate. percent change= \[(Glomerular Filtration Rate at Month 24-Glomerular Filtration Rate at baseline)/Glomerular Filtration Rate at baseline\]\*100 percent.
| percent change | Mycophenolate Mofetil + Sirolimus | Mycophenolate Mofetil + Cyclosporine or Tacrolimus |
|---|---|---|
| Baseline | 59.5 ± 23.86 | 58.8 ± 26.06 |
| Percent Change from Baseline at Month 24 | 8.6 ± 55.32 | 3.4 ± 67.28 |
Renal allograft function determined by mean percent change from baseline in serum creatinine by treatment group at 6, 12, and 24 months postrandomization. percent change= \[(serum creatinine at Month t-serum creatinine at baseline)/serum creatinine at baseline\]\*100 percent, where t=6, 12, and 24 months postrandomization.
| percent change | Mycophenolate Mofetil + Sirolimus | Mycophenolate Mofetil + Cyclosporine or Tacrolimus |
|---|---|---|
| Baseline | 121.1 ± 29.96 | 124.4 ± 37.87 |
| Percent Change from Baseline at Month 6 | -3.7 ± 18.78 | 6.6 ± 34.61 |
| Percent Change from Baseline at Month 12 | 6.0 ± 57.81 | 20.4 ± 92.81 |
| Percent Change from Baseline at Month 24 | 6.1 ± 59.84 | 30.8 ± 114.23 |
Renal allograft function determined by mean percent change from baseline in calculated creatinine clearance (Cockroft and Gault method) by treatment group at 6, 12, and 24 months postrandomization. percent change= \[(calculated creatinine clearance at Month t - calculated creatinine clearance at baseline)/calculated creatinine clearance at baseline\]\*100 percent, where t=6, 12, and 24 months postrandomization
| percent change | Mycophenolate Mofetil + Sirolimus | Mycophenolate Mofetil + Cyclosporine or Tacrolimus |
|---|---|---|
| Baseline | 59.7 ± 16.85 | 60.5 ± 19.97 |
| Percent Change from Baseline at Month 6 | 7.0 ± 19.54 | -1.7 ± 17.22 |
| Percent Change from Baseline at Month 12 | 4.4 ± 24.38 | -2.3 ± 25.09 |
| Percent Change from Baseline at Month 24 | 4.7 ± 27.58 | -4.2 ± 27.66 |
Renal allograft function determined by mean percent change from baseline in calculated Glomerular Filtration Rate (Nankivell equation) by treatment group at 6, 12, and 24 months postrandomization. percent change= \[(calculated Glomerular Filtration Rate at Month t - calculated Glomerular Filtration Rate at baseline)/calculated Glomerular Filtration Rate at baseline\]\*100 percent, where t=6, 12, and 24 months postrandomization.
| percent change | Mycophenolate Mofetil + Sirolimus | Mycophenolate Mofetil + Cyclosporine or Tacrolimus |
|---|---|---|
| Baseline | 71.3 ± 13.82 | 72.7 ± 16.2 |
| Percent Change from Baseline at Month 6 | 8.3 ± 19.57 | -0.5 ± 15.98 |
| Percent Change from Baseline at Month 12 | 5.2 ± 25.33 | -0.9 ± 23.42 |
| Percent Change from Baseline at Month 24 | 6.5 ± 28.43 | -1.8 ± 27.31 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mycophenolate Mofetil + Sirolimus | — | 60/148 (40.5%) | 147/148 (99.3%) |
| Mycophenolate Mofetil + Cyclosporine or Tacrolimus | — | 64/153 (41.8%) | 148/153 (96.7%) |
| Event | Mycophenolate Mofetil + Sirolimus | Mycophenolate Mofetil + Cyclosporine or Tacrolimus |
|---|---|---|
| PneumoniaInfections and infestations | 14/148 | 9/153 |
| Urinary Tract InfectionInfections and infestations | 5/148 | 8/153 |
| PyelonephritisInfections and infestations | 4/148 | 3/153 |
| CellulitisInfections and infestations | 4/148 | 1/153 |
| Chest PainGeneral disorders | 4/148 | 3/153 |
| PyrexiaGeneral disorders | 4/148 | 3/153 |
| UrosepsisInfections and infestations | 3/148 | 2/153 |
| Basal Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/148 | 3/153 |
| Deep Vein ThrombosisVascular disorders | 3/148 | 1/153 |
| Abdominal PainGastrointestinal disorders | 1/148 | 3/153 |
| Event | Mycophenolate Mofetil + Sirolimus | Mycophenolate Mofetil + Cyclosporine or Tacrolimus |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 51/148 | 50/153 |
| HyperlipidaemiaMetabolism and nutrition disorders | 44/148 | 20/153 |
| Oedema PeripheralGeneral disorders | 42/148 | 20/153 |
| LeukopeniaBlood and lymphatic system disorders | 36/148 | 29/153 |
| Urinary Tract InfectionInfections and infestations | 22/148 | 33/153 |
| HypertensionVascular disorders | 30/148 | 25/153 |
| Blood Creatinine IncreasedInvestigations | 14/148 | 31/153 |
| AnaemiaBlood and lymphatic system disorders | 25/148 | 17/153 |
| Upper Respiratory Tract InfectionInfections and infestations | 21/148 | 19/153 |
| Mouth UlcerationGastrointestinal disorders | 21/148 | 0/153 |
| Age Continuous(years) | Mycophenolate Mofetil + Sirolimus | Mycophenolate Mofetil + Cyclosporine or Tacrolimus | Total |
|---|---|---|---|
| Mean | 48.7 ± 12.90 | 48.7 ± 12.70 | 48.7 ± 12.80 |
| Sex: Female, Male(Participants) | Mycophenolate Mofetil + Sirolimus | Mycophenolate Mofetil + Cyclosporine or Tacrolimus | Total |
|---|---|---|---|
| Female | 55 | 55 | 110 |
| Male | 93 | 96 | 189 |
The record gives a start of Aug 2003, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus